Was the Takeda (TAK) insider sale related to taxes or discretionary selling?

The filing states it was a mandatory sale to cover taxes tied to the vesting of equity awards. This indicates the disposition was tax-driven rather than a discretionary portfolio reallocation.

Takeda executive sells shares to cover tax on awards

Q: What insider transaction did TAK report for Rhonda Janice Pacheco?

Rhonda Janice Pacheco reported a sale of 16,901 American Depositary Shares of Takeda on 2026-08-10. The transaction was required to cover taxes arising from the vesting of her equity awards.

Q: At what price were the Takeda (TAK) shares sold in this Form 4?

The shares were sold at a weighted average price of $17.10 per ADS. A footnote explains this average reflects multiple sale prices, and detailed price breakdowns are available upon request from the reporting person.

Q: How many Takeda (TAK) shares does Rhonda Pacheco hold after the transaction?

After the reported sale, Rhonda Pacheco directly holds 182,507 American Depositary Shares of Takeda. This figure represents her post-transaction direct ownership as disclosed in the Form 4.

Q: Does the Form 4 for Takeda (TAK) mention a Rule 10b5-1 trading plan?

The document-level Rule 10b5-1 checkbox is not marked as a plan transaction. The narrative instead specifies the sale was mandatory for tax withholding, with no additional trading-plan details provided.

Takeda Pharmaceutical Co Ltd executive Rhonda Janice Pacheco, President, U.S. Business Unit, reported the sale of 16,901 American Depositary Shares on 2026-08-10.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Takeda Pharmaceutical Co Ltd executive Rhonda Janice Pacheco, President, U.S. Business Unit, reported the sale of 16,901 American Depositary Shares on 2026-08-10. The transaction was a mandatory sale to cover taxes triggered by vesting of equity awards, executed at a $17.10 weighted average price per ADS. Following this tax-related sale, she directly holds 182,507 ADS.

Insider Trade Summary

Net Seller: 16,901 shares

Net Sell 1 txn

Insider Pacheco Rhonda Janice

Role President, U.S. Business Unit

Sold 16,901 shs ($289K)

Type	Security	Shares	Price	Value
Sale	American Depositary Shares ^{F1, F2}	16,901	$17.10	$289K

Holdings After Transaction: American Depositary Shares — 182,507 shares (Direct)

Footnotes (2)

F1. Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person.
F2. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Key Figures

Shares sold: 16,901 American Depositary Shares Weighted average sale price: $17.10 per ADS Shares held after transaction: 182,507 American Depositary Shares

3 metrics

Shares sold 16,901 American Depositary Shares Mandatory tax-cover sale on 2026-08-10

Weighted average sale price $17.10 per ADS Price reported for the 16,901 ADS sale

Shares held after transaction 182,507 American Depositary Shares Direct ownership after the 2026-08-10 sale

Key Terms

American Depositary Shares, mandatory sale to cover taxes, weighted average price

3 terms

American Depositary Shares financial

"The reporting person traded American Depositary Shares representing Takeda equity"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

mandatory sale to cover taxes financial

"Represents a mandatory sale to cover taxes associated with the vesting of equity awards"

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TAK report for Rhonda Janice Pacheco?

Rhonda Janice Pacheco reported a sale of 16,901 American Depositary Shares of Takeda on 2026-08-10. The transaction was required to cover taxes arising from the vesting of her equity awards.

At what price were the Takeda (TAK) shares sold in this Form 4?

The shares were sold at a weighted average price of $17.10 per ADS. A footnote explains this average reflects multiple sale prices, and detailed price breakdowns are available upon request from the reporting person.

How many Takeda (TAK) shares does Rhonda Pacheco hold after the transaction?

After the reported sale, Rhonda Pacheco directly holds 182,507 American Depositary Shares of Takeda. This figure represents her post-transaction direct ownership as disclosed in the Form 4.

Does the Form 4 for Takeda (TAK) mention a Rule 10b5-1 trading plan?

The document-level Rule 10b5-1 checkbox is not marked as a plan transaction. The narrative instead specifies the sale was mandatory for tax withholding, with no additional trading-plan details provided.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 08/12/2026 - 09:53 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pacheco Rhonda Janice

(Last)

(First)

(Middle)

500 KENDALL STREET

(Street)

CAMBRIDGE

MASSACHUSETTS

02142

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President, U.S. Business Unit

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
American Depositary Shares	08/10/2026		S⁽¹⁾		16,901	D	$17.1⁽²⁾	182,507	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person.

2. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

	/s/ Samuel Ntonme, by power of attorney, for Rhonda J. Pacheco	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR